433 related articles for article (PubMed ID: 34608598)
1. Sensitivity of two SARS-CoV-2 variants with spike protein mutations to neutralising antibodies.
Müller K; Girl P; Giebl A; Gruetzner S; Antwerpen M; Khatamzas E; Wölfel R; von Buttlar H
Virus Genes; 2021 Dec; 57(6):502-509. PubMed ID: 34608598
[TBL] [Abstract][Full Text] [Related]
2. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
3. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
4. Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.
Focosi D; Maggi F
Rev Med Virol; 2021 Nov; 31(6):e2231. PubMed ID: 33724631
[TBL] [Abstract][Full Text] [Related]
5. The effect of spike mutations on SARS-CoV-2 neutralization.
Rees-Spear C; Muir L; Griffith SA; Heaney J; Aldon Y; Snitselaar JL; Thomas P; Graham C; Seow J; Lee N; Rosa A; Roustan C; Houlihan CF; Sanders RW; Gupta RK; Cherepanov P; Stauss HJ; Nastouli E; ; Doores KJ; van Gils MJ; McCoy LE
Cell Rep; 2021 Mar; 34(12):108890. PubMed ID: 33713594
[TBL] [Abstract][Full Text] [Related]
6. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
Sheward DJ; Kim C; Ehling RA; Pankow A; Castro Dopico X; Dyrdak R; Martin DP; Reddy ST; Dillner J; Karlsson Hedestam GB; Albert J; Murrell B
Lancet Infect Dis; 2022 Jun; 22(6):813-820. PubMed ID: 35305699
[TBL] [Abstract][Full Text] [Related]
7. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.
Moyo-Gwete T; Madzivhandila M; Mkhize NN; Kgagudi P; Ayres F; Lambson BE; Manamela NP; Richardson SI; Makhado Z; van der Mescht MA; de Beer Z; de Villiers TR; Burgers WA; Ntusi NAB; Rossouw T; Ueckermann V; Boswell MT; Moore PL
J Virol; 2022 Aug; 96(15):e0055822. PubMed ID: 35867572
[TBL] [Abstract][Full Text] [Related]
8. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E
EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
[TBL] [Abstract][Full Text] [Related]
11. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies.
Alenquer M; Ferreira F; Lousa D; Valério M; Medina-Lopes M; Bergman ML; Gonçalves J; Demengeot J; Leite RB; Lilue J; Ning Z; Penha-Gonçalves C; Soares H; Soares CM; Amorim MJ
PLoS Pathog; 2021 Aug; 17(8):e1009772. PubMed ID: 34352039
[TBL] [Abstract][Full Text] [Related]
12. B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.
Zhou H; Dcosta BM; Samanovic MI; Mulligan MJ; Landau NR; Tada T
mBio; 2021 Aug; 12(4):e0138621. PubMed ID: 34311587
[TBL] [Abstract][Full Text] [Related]
13. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants.
Weigang S; Fuchs J; Zimmer G; Schnepf D; Kern L; Beer J; Luxenburger H; Ankerhold J; Falcone V; Kemming J; Hofmann M; Thimme R; Neumann-Haefelin C; Ulferts S; Grosse R; Hornuss D; Tanriver Y; Rieg S; Wagner D; Huzly D; Schwemmle M; Panning M; Kochs G
Nat Commun; 2021 Nov; 12(1):6405. PubMed ID: 34737266
[TBL] [Abstract][Full Text] [Related]
14. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
15. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants.
Mittal A; Khattri A; Verma V
PLoS Pathog; 2022 Feb; 18(2):e1010260. PubMed ID: 35176090
[TBL] [Abstract][Full Text] [Related]
16. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
Kim YJ; Jang US; Soh SM; Lee JY; Lee HR
Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138
[TBL] [Abstract][Full Text] [Related]
17. The great escape? SARS-CoV-2 variants evading neutralizing responses.
Prévost J; Finzi A
Cell Host Microbe; 2021 Mar; 29(3):322-324. PubMed ID: 33705702
[TBL] [Abstract][Full Text] [Related]
18. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.
Schmidt F; Weisblum Y; Rutkowska M; Poston D; DaSilva J; Zhang F; Bednarski E; Cho A; Schaefer-Babajew DJ; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Nature; 2021 Dec; 600(7889):512-516. PubMed ID: 34544114
[TBL] [Abstract][Full Text] [Related]
19. Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants.
Li T; Han X; Gu C; Guo H; Zhang H; Wang Y; Hu C; Wang K; Liu F; Luo F; Zhang Y; Hu J; Wang W; Li S; Hao Y; Shen M; Huang J; Long Y; Song S; Wu R; Mu S; Chen Q; Gao F; Wang J; Long S; Li L; Wu Y; Gao Y; Xu W; Cai X; Qu D; Zhang Z; Zhang H; Li N; Gao Q; Zhang G; He C; Wang W; Ji X; Tang N; Yuan Z; Xie Y; Yang H; Zhang B; Huang A; Jin A
Nat Commun; 2021 Nov; 12(1):6304. PubMed ID: 34728625
[TBL] [Abstract][Full Text] [Related]
20. Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion.
Salleh MZ; Derrick JP; Deris ZZ
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]